Drug intelligence / Profile preview

EV104A

Development stage: Preclinical
Lead developer: Enveric Biosciences
Modality: Small Molecules

Overview

**EV104A** is a preclinical, single-molecule cannabidiol and celecoxib conjugate developed by Enveric Biosciences using licensed technology from Diverse Biotech. It was designed for **osteoarthritis** and other pain conditions, with the objective of combining cannabidiol-associated analgesic and anti-inflammatory activity with celecoxib-associated cyclooxygenase-2 inhibition in a novel chemical entity intended to improve efficacy and tolerability relative to existing pain therapies. Enveric filed a provisional United States patent application covering EV104A and the related conjugate EV104B.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on EV104A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EV104A.

Explore the full profile